Entero Therapeutics Appoints Richard Paolone as CEO

Rhea-AI Summary

Entero Therapeutics (Nasdaq: ENTO) has announced the appointment of Richard Paolone as interim CEO. Paolone, a Toronto-based securities lawyer, brings extensive experience in corporate finance, securities law, and mergers and acquisitions to the clinical-stage biopharmaceutical company.

Paolone's background includes advising on strategic business initiatives, representing companies in debt and equity securities offerings, and demonstrating comprehensive knowledge of capital markets and regulatory environments. He has been instrumental in numerous M&A and go-public transactions, and has served as a director or officer for multiple private and publicly traded companies.

Positive

• Appointment of an experienced corporate finance and M&A professional as interim CEO
• New CEO brings extensive experience in capital markets and regulatory compliance
• Strong background in both private and public offerings of securities

Negative

• Interim nature of the CEO appointment indicates potential temporary leadership
• New CEO's background is primarily in legal and financial sectors rather than biotechnology or pharmaceuticals

BOCA RATON, Fla., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (Nasdaq: ENTO) (“Entero” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that the board of directors has appointed Mr. Richard Paolone as the interim CEO of the Company.

Richard Paolone is a Toronto-based securities lawyer with extensive experience in corporate finance, securities law, and mergers and acquisitions. Mr. Paolone plays a key role in advising on a range of strategic business initiatives and has represented numerous companies in both private and public offerings of debt and equity securities, comprehensive understanding of capital markets and regulatory environments. His advisory work has been pivotal to several successful M&A and go-public transactions.

In addition to his transactional work, Mr. Paolone has built a reputation as a trusted advisor to management teams and boards, ensuring legal and regulatory compliance in Canada while facilitating business growth. His broad experience also includes serving as a director or officer for several private and publicly traded companies, where he continues to provide strategic insights and governance expertise to help guide their success in competitive markets.

For more information about Entero Therapeutics, visit www.enterothera.com and connect on X and LinkedIn.

About Entero Therapeutics

Entero Therapeutics, Inc., is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company’s programs address significant unmet needs in GI health and include: latiglutenase, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. For more information visit www.enterothera.com. 

For more information:
Entero Therapeutics, Inc.
777 Yamato Road, Suite 502
Boca Raton, FL 33431
Phone: (561) 589-7020
info@enterothera.com

Investor contact information:
Entero Investor Relations
investors@enterothera.com

FAQ

Who is the new interim CEO of Entero Therapeutics (ENTO)?

Richard Paolone, a Toronto-based securities lawyer with extensive experience in corporate finance, securities law, and mergers and acquisitions, has been appointed as interim CEO of Entero Therapeutics.

What is Richard Paolone's background before joining ENTO as interim CEO?

Paolone has extensive experience in corporate finance, securities law, and M&A, having advised companies on strategic business initiatives, represented firms in debt and equity securities offerings, and served as director or officer for several private and public companies.

What are Richard Paolone's key areas of expertise as ENTO's new interim CEO?

Paolone's key areas of expertise include corporate finance, securities law, mergers and acquisitions, capital markets knowledge, regulatory compliance, and strategic business advisory.

When did Entero Therapeutics (ENTO) announce its new interim CEO appointment?

Entero Therapeutics announced the appointment of Richard Paolone as interim CEO on February 14, 2025.